Page 16 - Hal Barron News Today

Boy Scouts to honor Becker for supporting youth programs

The United States government announced plans to purchase sotrovimab, an investigational monoclonal antibody used for the early treatment of COVID-19

Investegate announcements from GlaxoSmithKline PLC, GSK shares positive Phase III data for daprodustat

/PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive results from the Phase III ASCEND (Anaemia Studies in Chronic Kidney Disease:...

Investegate announcements from GlaxoSmithKline PLC, Directorate Change

As the former boss of Glaxos consumer healthcare division, Emma Walmsley (pictured) has never been in doubt that it is a crown jewel buried within the pharmaceuticals and vaccine champion.

As the former boss of Glaxos consumer healthcare division, Emma Walmsley (pictured) has never been in doubt that it is a crown jewel buried within the pharmaceuticals and vaccine champion.

Nucala Approved for Chronic Rhinosinusitis With Nasal Polyps Credit: GlaxoSmithKline The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids. The approval was based on data from the randomized, double-blind, parallel group phase 3 SYNAPSE study (ClinicalTrials.gov Identifier: NCT03085797), w...

A failure to create a Covid vaccine has now become a symbol of what are believed to be bigger issues with Dame Emma’s leadership

FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19 The U.S. Food and Drug Administration (FDA) has given the green light on the investigational monoclonal antibody therapy, sotrovimab, as a treatment for coronavirus disease 2019 (COVID-19). The regulatory agency granted an Emergency Use Authorization (EUA) for sotrovimab, previously called VIR-7831, to treat mild to moderate COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The thera...